Is tadalafil appropriate for treating pulmonary arterial hypertension in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tadalafil for Pulmonary Arterial Hypertension

Yes, tadalafil 40 mg once daily is appropriate and FDA-approved for treating pulmonary arterial hypertension (WHO Group 1) in adults, with proven efficacy in improving exercise capacity, delaying clinical worsening, and enhancing quality of life. 1

Approved Indication and Dosing

Tadalafil is specifically approved for pulmonary arterial hypertension at 40 mg once daily 2. This once-daily dosing offers a practical advantage over sildenafil's three-times-daily regimen, improving adherence while maintaining comparable or superior efficacy 3.

Evidence of Efficacy

The pivotal PHIRST trial (n=405 patients) demonstrated that tadalafil 40 mg once daily:

  • Increased 6-minute walk distance by 33 meters (placebo-corrected, meeting the minimally important difference of 33m) 4
  • Reduced clinical worsening by 68% (relative risk reduction, P=0.038) 4
  • Improved health-related quality of life significantly 4
  • Extended time to clinical worsening (P=0.041) 4

Long-term extension data from PHIRST-2 showed sustained improvements in exercise capacity maintained for at least 52 weeks 5, 6.

Monotherapy vs. Combination Therapy

Treatment-naive patients: Tadalafil 40 mg as monotherapy increased 6MWD by 44 meters 4

Combination therapy: When added to background bosentan therapy, the benefit was 23 meters (not statistically significant in the original trial) 4. However, current guidelines strongly recommend initial combination therapy with an endothelin receptor antagonist (ERA) for WHO functional class II-III patients 3, 2. Recent systematic reviews suggest tadalafil + ERA combinations may show more favorable outcomes than sildenafil + ERA combinations 7.

Comparison to Sildenafil

While both PDE-5 inhibitors are effective, tadalafil offers:

  • Once-daily dosing vs. three-times-daily for sildenafil 3
  • Longer half-life (>2 days of active ingredient remaining in body) 1
  • Comparable or potentially superior efficacy when combined with ERAs 7
  • Similar side effect profile (headache, myalgia, flushing) 3, 4

Critical Safety Considerations

Absolute contraindications 1:

  • Nitrates (any form) - can cause life-threatening hypotension; must wait ≥48 hours after last tadalafil dose before nitrate administration
  • Guanylate cyclase stimulators (riociguat) - combination causes severe hypotension
  • Concurrent PDE-5 inhibitors (including sildenafil/Revatio)

Use with caution:

  • Alpha-blockers (risk of hypotension) 1
  • Antihypertensives (additive blood pressure lowering) 1
  • CYP3A4 inhibitors like ritonavir, ketoconazole, clarithromycin (increase tadalafil levels) 1

Monitor for:

  • Priapism (erections >4 hours require emergency care) 1
  • Sudden vision loss (NAION - stop drug immediately) 1
  • Sudden hearing loss (stop drug and seek medical attention) 1

Special Populations

CTD-associated PAH: Tadalafil remains effective but patients with connective tissue disease-associated PAH tend to have lower exercise capacity, higher rates of clinical worsening, and more adverse events compared to idiopathic/heritable PAH patients 5. The drug still provides benefit in this population.

WHO Group 2 PH (heart failure): Tadalafil is NOT recommended for heart failure with preserved ejection fraction and combined post/precapillary PH - the PASSION trial showed no clinical benefit 8. This is outside the approved indication 1.

Practical Implementation

Start tadalafil 40 mg once daily, taken at approximately the same time each day, with or without food 1. For patients on strong CYP3A4 inhibitors or with significant renal/hepatic impairment, dose adjustment may be necessary 1.

Current guideline-recommended approach 3, 2:

  • WHO-FC II-III PAH: Initial combination therapy (tadalafil + ERA like ambrisentan or macitentan)
  • Consider monotherapy only in lower-risk patients
  • Reassess at 3-6 months and escalate therapy if treatment goals not met

Common Pitfalls to Avoid

  1. Do not use lower doses - only 40 mg once daily showed statistically significant benefit in the pivotal trial 4
  2. Screen medication lists carefully for nitrates, riociguat, or other PDE-5 inhibitors before prescribing 1
  3. Educate patients that tadalafil remains active >2 days, critical for emergency nitrate administration decisions 1
  4. Do not use for WHO Group 2-5 PH without specific evidence - approval is only for Group 1 PAH 1, 8

References

Related Questions

How does tadalafil treat pulmonary arterial hypertension?
What is the appropriate tadalafil dose for an adult with pulmonary hypertension and a mean pulmonary artery pressure of 43 mmHg?
Is a beta‑blocker for hypertension safe to use together with tadalafil?
How should I manage a patient with primary pulmonary hypertension on Endobloc T (ambrisentan + tadalafil) who develops diarrhea and auxiliary lymphadenopathy?
Can a nitroglycerin infusion be safely initiated in a patient with severe hypertension (220/100 mmHg) who has taken tadalafil within the last 24‑48 hours?
What short‑acting benzodiazepine or alternative medication is appropriate for a generally healthy adult with acute flight‑related anxiety and no contraindications such as severe respiratory disease, severe liver impairment, glaucoma, pregnancy, or substance use disorder?
In a patient who experiences lightheadedness, dizziness, nausea, and headache upon standing, and who was started on lisinopril 10 mg orally daily and had his bupropion (Wellbutrin) increased from 300 mg to 450 mg, which medication is most likely causing these side effects?
In a 47-year-old male with total cholesterol 212 mg/dL, HDL cholesterol 28 mg/dL, triglycerides 670 mg/dL, hemoglobin A1c 5.9 %, glomerular filtration rate 98 mL/min/1.73 m², AST 24 U/L, and ALT 65 U/L, what is the appropriate starting dose of fenofibrate and should it be taken with meals?
What are the prophylactic options for recurrent uncomplicated Escherichia coli urinary tract infection?
What is the appropriate evaluation and management for a patient presenting with scleral icterus?
What does a TSH level of 5.82 µIU/mL indicate and what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.